Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Rhea-AI Summary
Absci (NASDAQ:ABSI) has announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI-driven drug discovery platform. The partnership leverages OCI's AI infrastructure and AMD's latest hardware, including next-generation Instinct™ MI355X GPUs, to accelerate biologics design cycles and reduce costs.
The collaboration enables Absci to perform large-scale molecular-dynamics simulations and end-to-end antibody design with improved efficiency. Using OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors, Absci has achieved ultra-low latency of 2.5 µs and terabytes-per-second throughput for data processing.
Positive
- Implementation of advanced AI infrastructure for accelerated drug discovery
- Reduced inter-GPU latency to as low as 2.5 µs
- Enhanced computational capabilities through Oracle and AMD partnership
- Improved efficiency in biologics design cycles
Negative
- None.
News Market Reaction
On the day this news was published, ABSI gained 15.13%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.7% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $56M to the company's valuation, bringing the market cap to $427M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.
To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD’s next generation Instinct™ MI355X GPUs.
“Our mission is to push the boundaries of how we design new therapeutics,” said Sean McClain, Founder and CEO, Absci. “With OCI and AMD, we are pairing our cutting-edge AI models with best‑in‑class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows.”
Scaling AI-driven drug discovery with OCI and AMD
OCI’s bare metal instances, powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA cluster networking, give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody–antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 µs, and benefit from terabytes-per-second throughput for checkpointing and data streaming.
“Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,” said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. “By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.”
“Absci is demonstrating how AI can transform the pace of drug discovery, and we’re proud to support that mission,” said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. “By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.”
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website, blog, LinkedIn, Facebook and X pages.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
AMD, EPYC, AMD Instinct, ROCm and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
Contact Info
Absci
press@absci.com
David Szabados
AMD Communications
david.szabados@amd.com
Julia Allyn
Oracle
julia.allyn@oracle.com
FAQ
What is the partnership between Absci, Oracle, and AMD focused on?
How does Oracle Cloud Infrastructure benefit Absci's drug discovery process?
What specific AMD technology is Absci using in this collaboration?
What performance improvements has Absci achieved through this collaboration?
How will this technology partnership impact Absci's drug development timeline?
